12772-57-5CC1CC2OC2/C=C\C=C\C(=O)Cc2c(Cl)c(O)cc(O)c2C(=O)O1WYZWZEOGROVVHK-HZDAAVBUSA-N12772-57-5DTXSID2042692Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
DescriptionRadicicol (12772-57-5) inhibits heat shock protein 90 (HSP90) activity by binding to the ATP-binding pocket.1In cells HSP90 client proteins such as Raf kinase2, HIF-1α3and estrogen receptor4are destabilized and proteolytically degraded. Radicicol inhibits expression of COX-2 without affecting COX-1 expression in LPS-stimulated macrophages (IC50=27 nM).5Inhibits angiogenesis.6
UsesRadicicol is a resorcylic acid lactone, produced by several fungal species, that exhibits broad spectrum antifungal and antitumour activity. Radicicol has been the subject of extensive investigation and inhibits protein tyrosine kinase, induces the differentiation of HL-60 cells into macrophages, blocks cell cycle at G1 and G2, suppresses NIH 3T3 cell transformation by diverse oncogenes such as src, ras and mos, and also suppresses the expression of mitogen-inducible cyclooxygenase-2. As a cell differentiation modulator, radicicol has anti-angiogenic activity in vivo, inhibiting the proliferation of plasminogen activator production by vascular endothelial cells.
UsesRadicicol is an antitumor antibiotic, which inhibits the Hsp90 molecular chaperone.
UsesRadicicol from Diheterospora chlamydosporia has been used as an inhibitor of heat shock protein 90 (Hsp90):to study its effects on lifespan extension and health in Caenorhabditis elegansto study its effects on protein aggregation in yeast to study its effects on xanthone sensitized cancer cells
No reaction records under the current filter.
Loading…
DefinitionChEBI: An antifungal macrolactone antibiotic, obtained from Diheterospora chlamydosporia and Chaetomium chiversii that inhibits protein tyrosine kinase and heat shock protein 90 (Hsp90).